{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:05:28Z","timestamp":1788408328966,"version":"build-2803163510"},"reference-count":33,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014470","name":"mundipharma international","doi-asserted-by":"publisher","award":["unrestricted grant"],"award-info":[{"award-number":["unrestricted grant"]}],"id":[{"id":"10.13039\/100014470","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Bendamustine, a medication approved for the treatment of indolent non-Hodgkin lymphoma, has already shown anticancer activity in metastatic breast cancer (MBC). Here, we present the results of a phase II trial of bendamustine in combination with capecitabine in pre-treated patients with MBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods:<\/jats:title>\n                    <jats:p>\n                      AGMT MBC-6 is a multicentre, open-label, single-arm phase II study in HER2-negative MBC. All patients were pre-treated with anthracyclines and\/or taxans and had measurable disease. Patients received per os 1000\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      capecitabine twice daily on days 1 to 14 in combination with 80\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      bendamustine intravenously on days 1 and 8 of a 3-week cycle for a maximum of eight cycles, followed by a capecitabine maintenance therapy. The primary endpoint was overall response rate (ORR).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>From September 2013 to May 2015, 40 patients were recruited in eight Austrian centres. The median age was 60\u2009years (range 29\u201377). Twenty-five per cent of patients had triple-negative breast cancer (TNBC) and 93% showed visceral involvement. With 17 partial and one complete remission, ORR was 46%. Median progression-free survival (PFS) was 7.5\u2009months [95% confidence interval (CI) 6.1\u201310.7]. The most common non-haematological adverse events (AEs) of grade 3 were hand-foot syndrome (13%), fatigue (10%), nausea (8%), and dyspnoea (8%). One grade 4 non-haematological AE (hepatic failure) and three grade 4 haematological AEs (neutropenia) were observed. One patient died of restrictive cardiomyopathy, in which a relationship to capecitabine cannot be excluded, but seems unlikely.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The combination of capecitabine and bendamustine shows promising efficacy and moderate toxicity. Further evaluation of this drug combination is warranted. The clinical trial AGMT MBC-6 was registered at ClinicalTrials.gov , ( https:\/\/clinicaltrials.gov\/ ; identifier: NCT01891227).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359211042301","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:56:33Z","timestamp":1634691393000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)"],"prefix":"10.1177","volume":"13","author":[{"given":"Gabriel","family":"Rinnerthaler","sequence":"first","affiliation":[{"name":"IIIrd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria"},{"name":"Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg, Austria"},{"name":"Cancer Cluster Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3966-1071","authenticated-orcid":false,"given":"Simon Peter","family":"Gampenrieder","sequence":"additional","affiliation":[{"name":"IIIrd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria"},{"name":"Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg, Austria"},{"name":"Cancer Cluster Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Petzer","sequence":"additional","affiliation":[{"name":"Internal Department I for Medical Oncology and Hematology, Barmherzige Schwestern Hospital\/Linz, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hubalek","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Innsbruck Medical University, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Petru","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Medical University Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Sandholzer","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and Gastroenterology, Infectiology, Academic Teaching Hospital Feldkirch, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Andel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Pyhrn-Eisenwurzen Klinikum Steyr, Steyr, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Balic","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Medical University Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Melchardt","sequence":"additional","affiliation":[{"name":"IIIrd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, AustriaSalzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Hauser-Kronberger","sequence":"additional","affiliation":[{"name":"Department of Pathology, Paracelsus Medical University Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens A.","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3 \u2013 Hematology and Oncology, Kepler University Hospital, Johannes Kepler University, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Ulmer","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics and Informatics, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[{"name":"IIIrd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria"},{"name":"Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg, Austria"},{"name":"Cancer Cluster Salzburg, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"bibr1-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-0975-5"},{"key":"bibr2-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy192"},{"key":"bibr3-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1159\/000154105"},{"key":"bibr4-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)84230-4"},{"key":"bibr5-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e328165d11a"},{"key":"bibr6-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1007\/s004320050225"},{"key":"bibr7-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm378"},{"key":"bibr8-17588359211042301","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/01.cad.0000175587.31940.19","volume":"16","author":"von Minckwitz G","year":"2005","journal-title":"Anticancer Drugs"},{"key":"bibr9-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.259"},{"key":"bibr10-17588359211042301","first-page":"39","volume":"12","author":"Bunnell CA","year":"1998","journal-title":"Oncology (Williston Park)"},{"key":"bibr11-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0015"},{"key":"bibr12-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.4244"},{"key":"bibr13-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.098"},{"key":"bibr14-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)71264-7"},{"key":"bibr15-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)01766-3"},{"key":"bibr16-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn592"},{"key":"bibr17-17588359211042301","first-page":"341","volume":"59","author":"Brockmann B","year":"1989","journal-title":"Arch Geschwulstforsch"},{"key":"bibr18-17588359211042301","first-page":"S324","volume":"35","author":"Schmidt P","year":"1999","journal-title":"ECCO"},{"key":"bibr19-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1159\/000335199"},{"key":"bibr20-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1159\/000510356"},{"key":"bibr21-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.167"},{"key":"bibr22-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"bibr23-17588359211042301","unstructured":"NCI. CTCAE version 4.03. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html (accessed 16 May 2017)."},{"key":"bibr24-17588359211042301","volume-title":"EORTC QLQ-C30 scoring manual","author":"Fayers P","year":"2001","edition":"3"},{"key":"bibr25-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.10.2756"},{"key":"bibr26-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1023\/B:BREA.0000036797.86601.cc"},{"key":"bibr27-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.485"},{"key":"bibr28-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A"},{"key":"bibr29-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600261"},{"key":"bibr30-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg346"},{"key":"bibr31-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.11.007"},{"key":"bibr32-17588359211042301","volume":"2013","author":"Dear RF","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr33-17588359211042301","doi-asserted-by":"publisher","DOI":"10.1002\/pon.3531"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359211042301","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359211042301","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359211042301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:26:21Z","timestamp":1777587981000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359211042301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":33,"alternative-id":["10.1177\/17588359211042301"],"URL":"https:\/\/doi.org\/10.1177\/17588359211042301","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"17588359211042301"}}